Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Quarterly results
BiomX Inc. (PHGE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
06/08/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/15/2023 8-K Quarterly results
Docs: "BiomX Reports First Quarter 2023 Financial Results and Provides Business Update"
05/05/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
03/29/2023 8-K Quarterly results
02/27/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Pre-Funded Warrant"
02/22/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "FORM OF PRE-FUNDED WARRANT",
"FORM OF SECURITIES PURCHASE AGREEMENT DATED FEBRUARY 22, 2023",
"FORM OF REGISTRATION RIGHTS AGREEMENT",
"INVESTOR PRESENTATION DATED FEBRUARY 22, 2023"
01/26/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "INVESTOR PRESENTATION DATED JANUARY 26, 2023"
01/06/2023 8-K Resignation/termination of a director
11/09/2022 8-K Quarterly results
08/29/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/10/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/30/2022 8-K Quarterly results
Docs: "CONSOLIDATED STATEMENTS OF OPERATIONS",
"INVESTOR PRESENTATION DATED MARCH 30, 2022"
11/15/2021 8-K Quarterly results
Docs: "BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update",
"INVESTOR PRESENTATION DATED NOVEMBER 15, 2021"
10/18/2021 8-K Other Events  Interactive Data
08/16/2021 8-K Quarterly results
07/26/2021 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financia...
Docs: "Form of Warrant",
"Opinion of Sullivan & Worcester LLP",
"Form of Securities Purchase Agreement, among BiomX Inc. and the Purchasers named therein",
"Placement Agency Agreement, among BiomX Inc., Cantor Fitzgerald & Co., and Chardan Capital Markets LLC"
06/21/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
12/04/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
12/04/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Restated Risk Factors"
11/12/2020 8-K Quarterly results
Docs: "About the BOLT Platform The newly unveiled BOLT R&D platform enables BiomX to rapidly develop, manufacture and formulate a phage treatment targeting a given pathogenic bacteria. The platform allows BiomX to conduct an initial clinical proof of concept study in patients within approximately 12-18 months of project initiation 1 . The ability to move quickly into clinical development is also driven by the strong safety profile of naturally-occurring phage, as corroborated by regulatory guidance provided to BiomX by the FDA as relating to its IBD program, allowing the Company to bypass safety studies and studies in healthy volunteers and to proceed directly to patient studies. 1 In certain indications the length of clinical proof of concept may be longer depending on indication, identity of ta...",
"Investor Presentation"
10/05/2020 8-K Quarterly results
08/13/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy